I recall Donna mentioning something about going to regulatory agencies, possibly the FDA, with data at the 6 month readout to inquire about the requirements for DMOAD. This will also be a great time to get the FDA to agree on an appropriate surrogate endpoint and possible pathway for accelerated approval.
The results for pain and function also present an interesting dilemma for the dose selection component for PARA 002 stage 1, since the two weekly dosage of 2mg/kg is not offered, so we need to hope that 2 x 1.5 mg/kg achieves the same response.
- Forums
- ASX - By Stock
- PAR
- Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial, page-35
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
29.8¢ |
Change
0.003(0.85%) |
Mkt cap ! $103.1M |
Open | High | Low | Value | Volume |
30.0¢ | 30.0¢ | 29.5¢ | $34.53K | 115.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 40539 | 29.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.5¢ | 56 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 40539 | 0.295 |
5 | 27379 | 0.290 |
3 | 52806 | 0.285 |
1 | 50000 | 0.280 |
1 | 5000 | 0.275 |
Price($) | Vol. | No. |
---|---|---|
0.285 | 56 | 1 |
0.305 | 10000 | 1 |
0.310 | 80900 | 3 |
0.315 | 58007 | 5 |
0.320 | 120187 | 5 |
Last trade - 15.59pm 22/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |